Mammotome is committed to providing best-in-class technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. As the global market leader in vacuum-assisted breast biopsy, Mammotome offers a wide range of products to help radiologists, surgeons and clinicians around the world using stereotactic, ultrasound, magnetic resonance imaging, or molecular imaging guidance.
Our entrepreneurial spirit challenges the status quo as we find innovative ways to help advance, improve and elevate the standards of patient care worldwide.
In 1995, Mammotome was introduced as the first vacuum-assisted biopsy system. Two years later, the Mammotome Biopsy System was acquired by Ethicon Endo-Surgery (EES), part of the Johnson & Johnson Family of Companies. EES continued to develop the Mammotome Biopsy System, creating additional image-guided products and developing the Mammotome brand into the worldwide market leader.
In July 2010, Devicor Medical Products, Inc. acquired the Breast Care Business from Ethicon Endo-Surgery. Devicor focuses exclusively on medical technologies that improve patient experiences and outcomes. Over the next several years, Devicor Medical launched two new innovative vacuum-assisted breast biopsy systems and acquired several other products to create a robust breast care product portfolio.
In December 2014, Devicor Medical Products was acquired by Leica Biosystems, part of the Danaher family of companies. Leica Biosystems is the global leader in anatomic pathology solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. The combination of the two companies uniquely positions us to develop integrated patient-to-pathology solutions for the diagnosis of cancer.
Headquartered in Cincinnati, Ohio, the Mammotome brand is sold in over 50 different countries throughout the world. Mammotome remains committed to its heritage of advancing technology for early detection of breast cancer, providing support and education for clinicians worldwide, and offering breast care information for patients.
To date, more than 5 million women worldwide have had a procedure using the minimally invasive Mammotome Biopsy System.
Mammotome currently employs over 600 people in the following countries:
- United States
- United Kingdom
- South Korea
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and laboratory automation for anatomical pathology, bringing clinicians and researchers high workflow efficiency and confidence in cancer diagnostics. Leica Biosystems provides a comprehensive product range with easy-to-use and consistently reliable solutions, from sample preparation and staining to imaging and reporting. At Leica Biosystems, we value our customers as partners, and therefore strive to deliver excellence in everything we do.
Danaher is a global science and technology innovator committed to helping our customers solve complex challenges and improve quality of life worldwide. Our world class brands are leaders in some of the most demanding and attractive industries. A globally diverse team of 71,000 associates, we are united by our culture and operating system, the Danaher Business System, which is our competitive advantage. In 2014, we generated $19.9B in revenue and our market cap exceeded $60B. We are #149 on the Fortune 500 and our stock has outperformed the S&P 500 by more than 2,000% over 20 years.